Possible FDA-approved drugs to treat Ebola virus infection

Infectious Diseases of Poverty

Volumn 4, Issue 1, 2015, Pages

  Yuan, Shu ^a  

^a SICHUAN AGRICULTURAL UNIVERSITY   (China)

Author keywords

Disseminated intravascular coagulation; Ebola virus infection; Glycosylation inhibitors; Miglustat; Niemann Pick C1 inhibitors; Toremifene

Indexed keywords

AMILORIDE; ANTISERUM; ANTIVIRUS AGENT; CHLOROQUINE; CLOMIFENE; FAVIPIRAVIR; HAPTOGLOBIN; IMATINIB; INTERFERON; KIDNEY INJURY MOLECULE 1; MIGLUSTAT; NILOTINIB; PROTHROMBIN; THROMBOPLASTIN; TOREMIFENE;

ANTIBODY DEPENDENT ENHANCEMENT; ANTIGEN BINDING; APOPTOSIS; BLOOD TRANSFUSION; CYTOLYSIS; DISSEMINATED INTRAVASCULAR CLOTTING; DOSE RESPONSE; DRUG CONCENTRATION; EBOLA HEMORRHAGIC FEVER; GLYCOSYLATION; HUMAN; MEMBRANE FUSION; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 84930188958     PISSN: 20955162     EISSN: 20499957     Source Type: Journal    
DOI: 10.1186/s40249-015-0055-z     Document Type: Review

References (51)

1. Wilson JA, Hevey M, Bakken R, Guest S, Bray M, Schmaljohn AL, et al. Epitopes involved in antibody-mediated protection from Ebola virus. Science. 2000;287:1664-6. Available: http://www.ncbi.nlm.nih.gov/pubmed/10698744. Accessed 10 December 2014.
2. Pettitt J, Zeitlin L, Kim Do H, Working C, Johnson JC, Bohorov O, et al. Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail. Sci Transl Med. 2013;5:199ra113. Available: http://www.ncbi.nlm.nih.gov/pubmed/23966302. Accessed 10 December 2014.
3. Warren TK, Warfield KL, Wells J, Swenson DL, Donner KS, Van Tongeren SA, et al. Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat Med. 2010;16:991-4. Available: http://www.ncbi.nlm.nih.gov/pubmed/20729866. Accessed 10 December 2014.
4. Warren TK, Wells J, Panchal RG, Stuthman KS, Garza NL, Van Tongeren SA, et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature. 2014;508:402-5. Available: http://www.ncbi.nlm.nih.gov/pubmed/24590073. Accessed 10 December 2014.
5. Geisbert TW, Lee AC, Robbins M, Geisbert JB, Honko AN, Sood V, et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet. 2010;375:1896-905. Available: http://www.ncbi.nlm.nih.gov/pubmed/20511019. Accessed 10 December 2014.
6. Qiu X, Wong G, Fernando L, Audet J, Bello A, Strong J, et al. mAbs and Ad-vectored IFN-α therapy rescue Ebola-infected nonhuman primates when administered after the detection of viremia and symptoms. Sci Transl Med. 2013;5:207ra143. Available: http://www.ncbi.nlm.nih.gov/pubmed/24132638. Accessed 10 December 2014.
7. Yuan S. Drugs to cure avian influenza infection - multiple ways to prevent cell death. Cell Death Dis. 2013;4:e835. Available: http://www.ncbi.nlm.nih.gov/pubmed/24091678. Accessed 10 December 2014.
8. Lee JE, Fusco ML, Hessell AJ, Oswald WB, Burton DR, Saphire EO. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature. 2008;454:177-82. Available: http://www.ncbi.nlm.nih.gov/pubmed/18615077. Accessed 20 December 2014.
9. Mohan GS, Li W, Ye L, Compans RW, Yang C. Antigenic subversion: a novel mechanism of host immune evasion by Ebola virus. PLoS Pathog. 2012;8:e1003065. Available: http://www.ncbi.nlm.nih.gov/pubmed/23271969. Accessed 20 December 2014.
10. Takada A, Feldmann H, Ksiazek TG, Kawaoka Y. Antibody-dependent enhancement of Ebola virus infection. J Virol. 2003;77:7539-44. Available: http://www.ncbi.nlm.nih.gov/pubmed/12805454. Accessed 20 December 2014.
11. Nakayama E, Tomabechi D, Matsuno K, Kishida N, Yoshida R, Feldmann H, et al. Antibody-dependent enhancement of Marburg virus infection. J Infect Dis. 2011;204(Suppl3):S978-85. Available: http://www.ncbi.nlm.nih.gov/pubmed/21987779. Accessed 20 December 2014.
12. Wauquier N, Becquart P, Padilla C, Baize S, Leroy EM. Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis. PLoS Negl Trop Dis. 2010;4:e837. Available: http://www.ncbi.nlm.nih.gov/pubmed/20957152. Accessed 20 December 2014.
13. Xu W, Edwards MR, Borek DM, Feagins AR, Mittal A, Alinger JB, et al. Ebola virus VP24 targets a unique NLS binding site on karyopherin alpha 5 to selectively compete with nuclear import of phosphorylated STAT1. Cell Host Microbe. 2014;16:187-200. Available: http://www.ncbi.nlm.nih.gov/pubmed/25121748. Accessed 10 December 2014.
14. García-Dorival I, Wu W, Dowall S, Armstrong S, Touzelet O, Wastling J, et al. Elucidation of the Ebola virus VP24 cellular interactome and disruption of virus biology through targeted inhibition of host cell protein function. J Proteome Res. 2014;13:5120-35. Available: http://www.ncbi.nlm.nih.gov/pubmed/25158218. Accessed 10 December 2014.
15. Kondratowicz AS, Lennemann NJ, Sinn PL, Davey RA, Hunt CL, Moller-Tank S, et al. T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and Lake Victoria Marburgvirus. Proc Natl Acad Sci USA. 2011;108:8426-31. Available: http://www.ncbi.nlm.nih.gov/pubmed/21536871. Accessed 10 December 2014.
16. Jemielity S, Wang JJ, Chan YK, Ahmed AA, Li W, Monahan S, et al. TIM-family proteins promote infection of multiple enveloped viruses through virion-associated phosphatidylserine. PLoS Pathog. 2013;9:e1003232. Available: http://www.ncbi.nlm.nih.gov/pubmed/23555248. Accessed 10 December 2014.
17. García M, Cooper A, Shi W, Bornmann W, Carrion R, Kalman D, et al. Productive replication of Ebola virus is regulated by the c-Abl1 tyrosine kinase. Sci Transl Med. 2012;4:123ra24. Available: http://www.ncbi.nlm.nih.gov/pubmed/22378924. Accessed 10 December 2014.
18. Gronchi A, Blay JY, Trent JC. The role of high-dose imatinib in the management of patients with gastrointestinal stromal tumor. Cancer. 2010;116:1847-58. Available: http://www.ncbi.nlm.nih.gov/pubmed/20166214. Accessed 25 December 2014.
19. + chronic myeloid leukemia in chronic phase. Eur J Clin Pharmacol. 2012;68:723-33. Available: http://www.ncbi.nlm.nih.gov/pubmed/22207416. Accessed 25 December 2014.
20. Cook JD, Lee JE. The secret life of viral entry glycoproteins: moonlighting in immune evasion. PLoS Pathog. 2013;9:e1003258. Available: http://www.ncbi.nlm.nih.gov/pubmed/23696729. Accessed 20 December 2014.
21. Mehta A, Zitzmann N, Rudd PM, Block TM, Dwek RA. Alpha-glucosidase inhibitors as potential broad based anti-viral agents. FEBS Lett. 1998;430:17-22. Available: http://www.ncbi.nlm.nih.gov/pubmed/9678587. Accessed 20 December 2014.
22. Chang J, Block TM, Guo JT. Antiviral therapies targeting host ER alpha-glucosidases: current status and future directions. Antiviral Res. 2013;99:251-60. Available: http://www.ncbi.nlm.nih.gov/pubmed/23816430. Accessed 10 December 2014.
23. Chang J, Warren TK, Zhao X, Gill T, Guo F, Wang L, et al. Small molecule inhibitors of ER α-glucosidases are active against multiple hemorrhagic fever viruses. Antiviral Res. 2013;98:432-40. Available: http://www.ncbi.nlm.nih.gov/pubmed/23578725. Accessed 10 December 2014.
24. Lennemann NJ, Rhein BA, Ndungo E, Chandran K, Qiu X, Maury W. Comprehensive functional analysis of N-linked glycans on Ebola virus GP1. MBio. 2014;5:e00862-13. Available: http://www.ncbi.nlm.nih.gov/pubmed/24473128. Accessed 20 December 2014.
25. Carette JE, Raaben M, Wong AC, Herbert AS, Obernosterer G, Mulherkar N, et al. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature. 2011;477:340-3. Available: http://www.ncbi.nlm.nih.gov/pubmed/21866103. Accessed 10 December 2014.
26. Côté M, Misasi J, Ren T, Bruchez A, Lee K, Filone CM, et al. Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. Nature. 2011;477:344-8. Available: http://www.ncbi.nlm.nih.gov/pubmed/21866101. Accessed 10 December 2014.
27. Shoemaker CJ, Schornberg KL, Delos SE, Scully C, Pajouhesh H, Olinger GG, et al. Multiple cationic amphiphiles induce a Niemann-Pick C phenotype and inhibit Ebola virus entry and infection. PLoS One. 2013;8:e56265. Available: http://www.ncbi.nlm.nih.gov/pubmed/23441171. Accessed 10 December 2014.
28. Johansen LM, Brannan JM, Delos SE, Shoemaker CJ, Stossel A, Lear C, et al. FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Sci Transl Med. 2013;5:190ra79. Available: http://www.ncbi.nlm.nih.gov/pubmed/23785035. Accessed 10 December 2014.
29. Gehring G, Rohrmann K, Atenchong N, Mittler E, Becker S, Dahlmann F, et al. The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry. J Antimicrob Chemother. 2014;69:2123-31. Available: http://www.ncbi.nlm.nih.gov/pubmed/24710028. Accessed 10 December 2014.
30. Saeed MF, Kolokoltsov AA, Albrecht T, Davey RA. Cellular entry of ebola virus involves uptake by a macropinocytosis-like mechanism and subsequent trafficking through early and late endosomes. PLoS Pathog. 2010;6:e1001110. Available: http://www.ncbi.nlm.nih.gov/pubmed/20862315. Accessed 20 December 2014.
31. Hunt CL, Kolokoltsov AA, Davey RA, Maury W. The Tyro3 receptor kinase Axl enhances macropinocytosis of Zaire ebolavirus. J Virol. 2011;85:334-47. Available: http://www.ncbi.nlm.nih.gov/pubmed/21047970. Accessed 10 December 2014.
32. Gnirss K, Kühl A, Karsten C, Glowacka I, Bertram S, Kaup F, et al. Cathepsins B and L activate Ebola but not Marburg virus glycoproteins for efficient entry into cell lines and macrophages independent of TMPRSS2 expression. Virology. 2012;424:3-10. Available: http://www.ncbi.nlm.nih.gov/pubmed/22222211. Accessed 10 December 2014.
33. Misasi J, Chandran K, Yang JY, Considine B, Filone CM, Côté M, et al. Filoviruses require endosomal cysteine proteases for entry but exhibit distinct protease preferences. J Virol. 2012;86:3284-92. Available: http://www.ncbi.nlm.nih.gov/pubmed/22238307. Accessed 10 December 2014.
34. Marzi A, Reinheckel T, Feldmann H. Cathepsin B & L are not required for ebola virus replication. PLoS Negl Trop Dis. 2012;6:e1923. Available: http://www.ncbi.nlm.nih.gov/pubmed/23236527. Accessed 20 December 2014.
35. World Health Organization. potential Ebola therapies and vaccines. 2014. Available: http://www.who.int/csr/disease/ebola/ebola-new-interventions-02-sep-2014.pdf. Accessed 2 October 2014.
36. Firuzi O, Miri R, Tavakkoli M, Saso L. Antioxidant therapy: current status and future prospects. Curr Med Chem. 2011;18:3871-88. Available: http://www.ncbi.nlm.nih.gov/pubmed/21824100. Accessed 25 December 2014.
37. Lai KY, Ng WYG, Cheng FF. Human Ebola virus infection in West Africa: a review of available therapeutic agents that target different steps of the life cycle of Ebola virus. Infect Dis Poverty. 2014;3:43. Available: http://www.ncbi.nlm.nih.gov/pubmed/25699183. Accessed 25 December 2014.
38. van Giersbergen PL, Dingemanse J, van Giersbergen PL, Dingemanse J. Influence of food intake on the pharmacokinetics of miglustat, an inhibitor of glucosylceramide synthase. J Clin Pharmacol. 2007;47:1277-82. Available: http://www.ncbi.nlm.nih.gov/pubmed/17720777. Accessed 25 December 2014.
39. Rostami-Hodjegan A, Lennard MS, Tucker GT, Ledger WL. Monitoring plasma concentrations to individualize treatment with clomiphene citrate. Fertil Steril. 2004;81:1187-93. Available: http://www.ncbi.nlm.nih.gov/pubmed/15136073. Accessed 25 December 2014.
40. Szutu M, Morgan DJ, McLeish M, Phillipou G, Blackman GL, Cox LW, et al. Pharmacokinetics of intravenous clomiphene isomers. Br J Clin Pharmacol. 1989;27:639-40. Available: http://www.ncbi.nlm.nih.gov/pubmed/2757886. Accessed 25 December 2014.
41. Lara Jr PN, Gandara DR, Wurz GT, Lau D, Uhrich M, Turrell C, et al. High-dose toremifene as a cisplatin modulator in metastatic non-small cell lung cancer: targeted plasma levels are achievable clinically. Cancer Chemother Pharmacol. 1998;42:504-8. Available: http://www.ncbi.nlm.nih.gov/pubmed/9788578. Accessed 25 December 2014.
42. Rosenbaum AI, Maxfield FR. Niemann-Pick type C disease: molecular mechanisms and potential therapeutic approaches. J Neurochem. 2011;116:789-95. Available: http://www.ncbi.nlm.nih.gov/pubmed/20807315. Accessed 25 December 2014.
43. Lyseng-Williamson KA. Miglustat: a review of its use in Niemann-Pick disease type C. Drugs. 2014;74:61-74. Available: http://www.ncbi.nlm.nih.gov/pubmed/24338084. Accessed 25 December 2014.
44. Geisbert TW, Young HA, Jahrling PB, Davis KJ, Larsen T, Kagan E, et al. Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol. 2003;163:2371-82. Available: http://www.ncbi.nlm.nih.gov/pubmed/14633609. Accessed 20 December 2014.
45. Paessler S, Walker DH. Pathogenesis of the viral hemorrhagic fevers. Annu Rev Pathol. 2013;8:411-40. Available: http://www.ncbi.nlm.nih.gov/pubmed/23121052. Accessed 20 December 2014.
46. Kaplan AP, Joseph K. Pathogenic mechanisms of bradykinin mediated diseases: dysregulation of an innate inflammatory pathway. Adv Immunol. 2014;121:41-89. Available: http://www.ncbi.nlm.nih.gov/pubmed/24388213. Accessed 25 December 2014.
47. Wada H, Matsumoto T, Yamashita Y, Hatada T. Disseminated intravascular coagulation: Testing and diagnosis. Clin Chim Acta. 2014;436C:130-4. Available: http://www.ncbi.nlm.nih.gov/pubmed/24792730. Accessed 25 December 2014.
48. Di Nisio M, Baudo F, Cosmi B, D'Angelo A, De Gasperi A, Malato A, et al. Diagnosis and treatment of disseminated intravascular coagulation: guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thromb Res. 2012;129(5):e177-84. Available: http://www.ncbi.nlm.nih.gov/pubmed/21930293. Accessed 25 December 2014.
49. Levy AP, Asleh R, Blum S, Levy NS, Miller-Lotan R, Kalet-Litman S, et al. Haptoglobin: basic and clinical aspects. Antioxid Redox Signal. 2010;12:293-304. Available: http://www.ncbi.nlm.nih.gov/pubmed/19659435. Accessed 25 December 2014.
50. Schaer DJ, Buehler PW, Alayash AI, Belcher JD, Vercellotti GM. Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins. Blood. 2013;121:1276-84. Available: http://www.ncbi.nlm.nih.gov/pubmed/23264591. Accessed 25 December 2014.
51. Borchert M, Mutyaba I, Van Kerkhove MD, Lutwama J, Luwaga H, Bisoborwa G, et al. Ebola haemorrhagic fever outbreak in Masindi District, Uganda: outbreak description and lessons learned. BMC Infect Dis. 2011;11:357. Available: http://www.ncbi.nlm.nih.gov/pubmed/22204600. Accessed 25 December 2014.